Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) issued an announcement. Preliminary research data on GFH276 (oral molecular gum RAS inhibitor) for treating solid tumors with RAS mutations appeared in the groundbreaking research summary and live oral report at the ESMO (European Society of Medical Oncology) Annual Meeting on October 25, local time. GFH276 has shown encouraging initial efficacy and good safety during the dose escalation phase: partial remission (PR) was observed in patients starting at the 40 mg QD dose level; no dose-limiting toxicity (DLTs) was observed at the 40-160 mg QD dose level when patients were not using prophylactic agents.
Zhitongcaijing · 3d ago
Share
Listen to the news
Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) issued an announcement. Preliminary research data on GFH276 (oral molecular gum RAS inhibitor) for treating solid tumors with RAS mutations appeared in the groundbreaking research summary and live oral report at the ESMO (European Society of Medical Oncology) Annual Meeting on October 25, local time. GFH276 has shown encouraging initial efficacy and good safety during the dose escalation phase: partial remission (PR) was observed in patients starting at the 40 mg QD dose level; no dose-limiting toxicity (DLTs) was observed at the 40-160 mg QD dose level when patients were not using prophylactic agents.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending